Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY
Alnylam Pharmaceuticals — Q2 2024 Earnings Presentation
30 slides from Alnylam Pharmaceuticals's earnings presentation, Aug 1, 2024
Slide 1: Second Quarter 2024 Financial Results
Second Quarter 2024 Financial Results August 1, 2024 © 2024 Alnylam Pharmaceuticals, Inc. 1
Slide 2: Agenda
Agenda Welcome • Christine Lindenboom Senior Vice President, Investor Relations & Corporate Communications Overview • Yvonne Greenstreet, MBChB, MBA Chief Executive Officer Commercial Highlights • Tolga Tanguler Chief Commercial Officer Alnylam Pipeline • Pushkal Garg, M.D. Chief Medical Officer Fin
Slide 3: Alnylam Forward Looking Statements
Alnylam Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, b
Slide 4: Overview
Yvonne Greenstreet, MBChB, MBA Chief Executive Officer Overview 4
Slide 5: Q2 2024 Highlights
Q2 2024 Highlights Strong Increased Positive HELIOS-B Revenue Growth Financial Guidance Topline Results • $410 million net product • 11% increase in net product • Potential for standard of care revenues revenue guidance at midpoint • Well positioned to address • 34% YoY growth1 significant unmet nee
Slide 6: Ambitious Five-Year Strategy to Drive Growth
Ambitious Five-Year Strategy to Drive Growth Patients: Over 0.5 million on Alnylam RNAi therapeutics globally Products: 6+ marketed products in rare and prevalent diseases Pipeline: Over 20 clinical programs, with 10+ in late stages and 4+ INDs per year Performance: ≥40% revenue CAGR through YE 2025
Slide 7: TTR Investor Day
SAVE THE DATE TTR Investor Day October 9, 2024 8:30 am ET | NYC & Webcast Registration information forthcoming 7
Slide 8: Commercial Highlights
Tolga Tanguler Chief Commercial Officer Commercial Highlights 8
Slide 9: Commercial Portfolio
Commercial Portfolio Continued Strong Performance in Q2 2024 Overall Portfolio $410M 34% 12% Combined Net Product Revenue YoY growth1 vs. Q2’23 QoQ growth1 vs. Q1’24 TTR Franchise Rare Franchise 9 1 With FX impact. For growth at CER = constant exchange rate – see the Financial Summary slide for more
Slide 10: TTR Franchise Update: Q2 2024
TTR Franchise Update: Q2 2024 $307M Total TTR Global Q2 2024 Net Product Revenues Q2 TTR Franchise Highlights YoY % Growth QoQ % Growth +37% +16% U.S. 40% 16% $307M ROW 35% 16% $264M Global 37% 16% $254M $82M $224M $230M • U.S. TTR franchise YoY growth of +40% driven by: $53M $65M – Demand (+34%): c
Slide 11: Significant Unmet Need Remains Among ATTR-CM Patients
Significant Unmet Need Remains Among ATTR-CM Patients • Diagnostic rates rapidly 200-300K patients globally1 ~80% ATTR-CM patients improving • Analogues suggest competition accelerates untreated globally1 category growth • HCPs prioritize impact on mortality, CV events Treated ~75% and functional ca
Slide 12: Vutrisiran Well Positioned for Market-Leading Profile in ATTR-CM
Vutrisiran Well Positioned for Market-Leading Profile in ATTR-CM • Targeted RNAi mechanism enables rapid knockdown Unique MOA of pathogenic protein at the source • Works upstream of approved medicine Features Physicians Consistently Look for • Significant reduction in mortality and CV hospitalizatio
Slide 13: Alnylam Prepared to Move Quickly with Proven Commercial Engine in TTR
Alnylam Prepared to Move Quickly for Rapid Impact with Proven Commercial Engine in TTR Franchise Focused Customer- Deep experience with Facing Teams TTR Centers Delivering seamless Well positioned to serve unmet customer experiences, needs of ATTR-CM patients differentiating in competitive landscape
Slide 14: Rare Franchise Update: Q2 2024
Rare Franchise Update: Q2 2024 $103M Total Rare Global Q2 2024 Net Product Revenues Q2 Rare Franchise Highlights +25% +2% YoY % Growth QoQ % Growth $103M $101M GIVLAARI 7% 7% $92M $25M OXLUMO 68% -5% $82M $83M $29M $22M Total Rare 25% 2% $15M $19M $16M $11M $13M • GIVLAARI YoY growth of +7% driven b
Slide 15: Alnylam Pipeline
Pushkal Garg, M.D. Chief Medical Officer Alnylam Pipeline 15
Slide 16: HELIOS-B: Positive Topline Results
HELIOS:B POSITIVE TOPLINE RESULTS
Slide 17: Data Support Potential for Vutrisiran as Standard of Care in ATTR-CM
Data Support Potential for Vutrisiran as Standard of Care in ATTR-CM Relative Risk Reduction Versus Placebo Composite of all-cause mortality and recurrent CV events (primary endpoint) All-cause mortality (secondary endpoint) Clinically significant benefits on Overall Monotherapy Overall Monotherapy
Slide 18: Next Steps
Next Steps HELIOS-B Full Results – ESC Congress (August 30, London) Global Regulatory Submissions – Late 2024 Priority Review Voucher to Accelerate FDA Review 18
Slide 19: Advancing a Robust and High-Yielding Pipeline of RNAi Therapeutics
Advancing a Robust and High-Yielding Pipeline of RNAi Therapeutics Positioned to Deliver Strong Growth and Innovation Across Multiple Disease Areas and Indications IND-enabling Phase 1 Phase 2 Phase 3 Approved ALN-HTT02* ALN-TTRsc04 Zilebesiran* Vutrisiran Huntington’s Disease ATTR Amyloidosis Hyper
Slide 20: Partnered Program Updates
Partnered Program Updates FITUSIRAN Hemophilia • Regulatory filings submitted in China, Brazil, and U.S. • FDA target action date March 28, 2025 CEMDISIRAN MIVELSIRAN Complement-Mediated Diseases Alzheimer’s Disease & Cerebral Amyloid Angiopathy • Regeneron gained exclusive rights to • Alnylam assum
Slide 21: Multiple Sources of Sustainable Innovation Drive Robust Pipeline
Multiple Sources of Sustainable Innovation Drive Robust Pipeline Targeting Nine Alnylam-Led INDs Across Four Tissues by End of 2025 Extrahepatic Delivery Platform Designs Human Genetics 12 months IKARIA™ Reversir™ GEMINI™ By End of 2025 new liver new CNS 5 INDs 2 INDs 2 new tissues with INDs 10+ inc
Slide 22: Financial Summary and Upcoming Milestones
Jeff Poulton Chief Financial Officer Financial Summary and Upcoming Milestones 22
Slide 23: Q2 2024 Financial Summary
Q2 2024 Financial Summary Q2 Reported Q2 CER Financial Results ($ millions) Q2 2024 Q2 2023 Growth % Growth %2 Net Product Revenues $410 $306 34% 35% Net Revenues from Collaborations $227 $6 Royalty Revenues $22 $7 Total Revenues $660 $319 107% 108% Product Cost of Goods Sold $67 $75 Cost of Collabo
Slide 24: 2024 Updated Full Year Guidance
2024 Updated Full Year Guidance Prior FY 2024 Guidance Updated FY 2024 Guidance Net Product Revenue1 ONPATTRO, AMVUTTRA, GIVLAARI, $1,400M - $1,500M $1,575M - $1,650M OXLUMO Net Product Revenue Growth vs. 2023 at reported FX rates1 13% to 21% 27% to 33% Net Product Revenue Growth vs. 2023 at constan
Slide 25: Alnylam 2024 Goals
Alnylam 2024 Goals Early Mid Late Combined Net Product Revenue Guidance $1,575M – $1,650M HELIOS-B Topline Results VUTRISIRAN ATTR Amyloidosis sNDA Submission ALN-TTRsc04* ATTR Amyloidosis Initiate Phase 3 ATTR-CM Study KARDIA-2 Phase 2 Topline Results ZILEBESIRAN* Hypertension Initiate KARDIA-3 Pha
Slide 26: Q&A Session
Q2 2024 Financial Results Q&A Session 26
Slide 27: Thank You!
| || Thank You! “LAlnylam
Slide 28: Appendix
Q2 2024 Financial Results Appendix 28
Slide 29: Reconciliation of Selected GAAP Measures to Non-GAAP Measures
Alnylam Pharmaceuticals, Inc. Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands, except per share amounts) 29 Please note that the figures presented may not sum exactly due to rounding
Slide 30: Reconciliation of Revenue and Growth at Constant Currency
Alnylam Pharmaceuticals, Inc. Reconciliation of Revenue and Growth at Constant Currency Please note that the figures presented may not sum exactly due to rounding 30 Constant Currency = Constant Exchange Rate, or CER
Alnylam Pharmaceuticals — Q2 2024 Earnings Presentation on 6ix